Who Should Be Tested?

Women with unexplained infertility

Women with unexpected IVF failure

Women with limited embryo reserves

Women experiencing recurrent pregnancy loss

Women who cannot afford IVF or that have limited fertility coverage

What physicians are saying about ReceptivaDx testing

"When a patient has high quality, genetically screened embryos and still can't become pregnant, ReceptivaDx has provided answers for our patients when we had no other known explanations for their transfer failure history."

Lora Shahine, MD, - Pacific NW Fertility
Seattle, WA

"ReceptivaDx™ provides unique information for our patients with unexplained infertility, failed IVF history and those with recurrent pregnancy loss. In the past, so many of these patients would simply give up. The test has made a significant difference for our practice."

Sunny Jun, MD - CCRM San Francisco Menlo Park, CA

"ReceptivaDx has given me insight into previously unexplained infertility and failed IVF along with treatment options for my patients."

Mira Aubuchon, M.D. - MCRM Fertility Chesterfield, Missouri

"Endometriosis/uterine receptivity defects are common and in this 'no laparoscopy' era, ReceptivaDx is essential for diagnosis and treatment planning."

Alex Steinleitner, M.D. Physician - Central Coast Fertility San Luis Obispo, CA

Getting Tested

Over 250 Fertility Centers in the US offer ReceptivaDx. In addition to fertility centers listed on our website, patients can request a collection kit for future testing at a fertility center or Ob-Gyn office near them. Everything needed to properly submit a sample is included in the kit. Please call our customer service desk at 800-795-5385 for further assistance.

Sample Requirements

An endometrial biopsy is collected during the window of implantation in either a natural cycle or controlled "mock cycle". Accurate biopsy timing is important to the quality of results

Natural Cycle: 7-10 days after ovulation

Mock Cycle: 5-10 days after start of progesterone

Cost of Testing

A complete pathology report and interpretation of the BCL6 marker is \$690 US dollars. Beta 3 Integrin (marker of overall uterine receptivity) and CD138 (marker for endometritis), can be added to your ReceptivaDx panel for an additional \$125 per marker. Overnight shipping via FedEx from within the US is also covered in the cost. International customers are eligible for US pricing, but must arrange shipping at their own expense. Payment is required at the time of testing before any sample can be processed. A detailed receipt will be provided to patients to help with reimbursement from insurance or healthcare spending accounts. CiceroDx does not contract with or bill insurance.

Test Results

Results are faxed to referring physicians 4-5 days from date our lab receives the sample.

CiceroDx, Inc.


Is the exclusive provider of ReceptivaDx (BCL6 Analysis)

Our Mission: CiceroDx is dedicated to the transfer of new technologies to advance global healthcare for women.

For More Information: www.receptivadx.com (800) 795-5385



BCL6 AnalysisPatient Information



She planned for a family, not for IVF failure.

It's time to introduce ReceptivaDx testing and get answers for your unexplained infertility

What is ReceptivaDx?

ReceptivaDx detects inflammation on the uterine lining, a sign of previously undetected endometriosis. The test can also detect recurring endometriosis in patients previously diagnosed and treated for the condition.

Endometriosis is considered to be the leading cause of unexplained infertility, IVF transfer failure and recurrent pregnancy loss.

ReceptivaDx provides new answers and new treatment pathways even in situations where genetic testing of embryos and attempts to define optimal transfer windows have failed to yield a successful pregnancy.

Based on an endometrial biopsy, ReceptivaDx measures a protein called BCL6. Validation studies demonstrated a 93% sensitivity and 96% specificity between a positive BCL6 result and a confirmed diagnosis of endometriosis.

75% of Women

With unexplained infertility will test positive for BCL6

82% of Women

With a history of 2 or more failed IVF transfers will test positive for BCL6

Above data based on previously published clinical data in addition to over 2500 samples analyzed by ReceptivaDx

"Women testing positive for BCL6 are 5 times less likely to succeed in IVF than women with a negative test result."




Bruce Lessey, M.D., Ph.D.
Scientific Advisor
CiceroDx, Inc.

What do my ReceptivaDx test results mean and what treatment options are available?

- If negative for BCL6, women can be confident that endometriosis is not the underlying issue and future IVF success rates will be consistent with the general IVF patient population.
- **If positive for BCL6**, inflammation on the uterine lining is the likely cause of implantation failure. This inflammation is caused by the body's immune response to previously undetected endometriosis.
- A treatment plan involving hormone therapy or laparoscopy to suppress or remove visible endometriosis can correct the situation.
- In a recent clinical study*, BCL6 positive patients undergoing 60 days of hormone suppression therapy or laparoscopic surgery demonstrated excellent success on their next transfer attempt (see graph below).
- Risk of miscarriage was dramatically reduced in patients receiving treatment when compared to women in the control group that did not receive treatment after a positive BCL6 result.

Treatment Outcome Comparisons of BCL6 Positive Patients

Hormone Suppression Therapy (Depot Lupron) vs Laparoscopy vs Control Group (No treatment)



^{*} Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression - Journal of Assisted Reproduction & Genetics 2019 Jan 4

Over 250 Fertility Centers in the US & around the World now offer ReceptivaDx. Visit www.receptivadx.com for more information and to find a center near you.